[Federal Register: August 27, 2004 (Volume 69, Number 166)]
[Notices]
[Page 52721-52722]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr27au04-52]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[CMS-5025-CN]
RIN 0938-ZA51
Medicare Program; Medicare Replacement Drug Demonstration;
Correction
AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.
ACTION: Notice; correction.
-----------------------------------------------------------------------
SUMMARY: This document corrects technical and typographical errors that
appeared in the notice published in the Federal Register on June 29,
2004 entitled ``Medicare Replacement Drug Demonstration (69 FR
38898).'' That notice announced the implementation of a demonstration
that would pay through December 31, 2005 under Medicare Part B for
drugs and biologicals that are prescribed as replacements for existing
covered Medicare drugs and biologicals described in section
1861(s)(2)(A) or 1861(s)(2)(Q), or both, of title XVIII of the Social
Security Act.
DATES: Effective June 29, 2004.
FOR FURTHER INFORMATION CONTACT: Jody Blatt, (410) 786-6921.
SUPPLEMENTARY INFORMATION:
I. Background
In FR Doc. 04-14673 of June 29, 2004 (69 FR 38898), there were a
number of technical and typographical errors that are identified and
corrected in the Correction of Errors section below. The provisions in
this correction notice are effective as if they were included in the
document published June 29, 2004. Accordingly, the corrections are
effective June 29, 2004.
II. Correction of Errors
In FR Doc. 04-14673 of June 29, 2004 (69 FR 38898), make the
following corrections:
1. On page 38899, in the table, in the first column, the term
entitled ``Chronic Myelogenous Lymphoma'' is corrected to read
``Chronic Myelogenous Leukemia.''
2. On page 38899, in the table, in the first column, the term
entitled ``Anaplastic astrocytoma'' is removed. Temodar, which treats
anaplastic astrocytoma, is already covered under Medicare Part B and
will not be covered under this demonstration.
3. On page 38899, in the table, in the second column, the drug
entitled ``Pegalated interferon alfa-2a (PEG-Intron)'' is corrected to
read ``Pegylated interferon alfa-2b (PEG-Intron).''
4. On page 38899, in the table, in the second column the drug
entitled ``Temozolomide (Temodar)'' is removed. Temodar is already
covered under Medicare Part B and will not be covered under this
demonstration.
5. On page 38900, in the first column, in the fourth paragraph, in
the seventh and eighth lines, the words ``Advance PCS, a Caremark
Company (Caremark),'' are corrected to read ``Caremark.'' The correct
reference to this company is Caremark, not Advance PCS, a Caremark
Company.
6. On page 38902, in the third column, in the first through eighth
lines, remove the sentence ``The rules for low-income assistance,
including coverage levels and determination of eligibility, have been
established to be consistent with what will be in effect in 2006 when
the Medicare Part D drug benefit is implemented.'' Rules established
for this demonstration apply only to this demonstration and do not
necessarily reflect how the Medicare Part D benefit will be
implemented.
7. On page 38903, in Table 1A, the following sentence is added to
the footnote, ``Under the different low income benefit levels,
subsidies by Medicare as well as out-of-pocket payments by the
beneficiary count towards the out-of-pocket catastrophic limit.''
8. On page 38904, in Table 1B, in the second column, under the
heading entitled ``Benefit Level 1 (Standard),'' in the third row, the
amount ``$1,350'' is corrected to read ``$2,850.''
9. On page 38904, in Table 1B, the following sentence is added to
the footnote, ``Under the different low income benefit levels,
subsidies by Medicare as well as out-of-pocket payments by the
beneficiary count towards the out-of-pocket catastrophic limit.''
III. Waiver of Proposed Rulemaking
We ordinarily publish a notice of proposed rulemaking in the
Federal Register to provide a period for public comment before the
provisions of a notice take effect. We can waive this procedure,
however, if we find good cause that notice and comment procedure is
impracticable, unnecessary, or contrary to the public interest and
incorporate a statement of the finding and the reasons for it into the
notice issued.
We find it unnecessary to undertake notice and comment rulemaking
because this notice merely provides technical corrections to the
notice.
[[Page 52722]]
Therefore, we find good cause to waive notice and comment procedures.
(Catalog of Federal Domestic Assistance Program No. 93.774,
Medicare--Supplementary Medical Insurance Program)
Dated: August 4, 2004.
Jacquelyn Y. White,
Director, Office of Strategic Operations and Regulatory Affairs.
[FR Doc. 04-18643 Filed 8-26-04; 8:45 am]
BILLING CODE 4120-01-P